celecoxib and Adenoma studies

Research Excerpts

Excerpt	Relevance	Reference
"Oxylipins derived from arachidonic acid (ARA) have been implicated in the development of colorectal adenomas and colorectal cancer."	9.41	A Protective Role for Arachidonic Acid Metabolites against Advanced Colorectal Adenoma in a Phase III Trial of Selenium. ( Chew, WM; Chow, HS; Ellis, NA; Jacobs, ET; Lance, P; Martinez, JA; Saboda, K; Skiba, MB, 2021)
"In the placebo and celecoxib arms of 356 participants each, adenoma detection was 47."	9.22	Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial. ( Ahnen, DJ; Alberts, DS; Ashbeck, EL; Bhattacharyya, A; Boland, CR; Buckmeier, J; Chow, SH; Fales, L; Fay, DE; Hamilton, SR; Heigh, RI; Hsu, CH; Jacobs, ET; Lance, P; Martinez, EM; Roe, DJ; Thompson, PA; Wang, F, 2016)
"Genetic polymorphisms in multiple inflammation-related genes appear to interact with celecoxib on adenoma recurrence and its attendant toxicity, particularly cardiovascular toxicity/symptoms."	9.17	Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. ( Arber, N; Coghill, AE; Duggan, D; Galazan, L; Gigic, B; Hummler, S; Kazanov, D; Kotzmann, J; Kraus, S; Makar, KW; Naumov, I; Poole, EM; Scherer, D; Toriola, AT; Ulrich, CM, 2013)
"COX inhibitors reduce colorectal adenoma recurrence by up to 45% and selenium supplementation may prevent colorectal cancer."	9.16	Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention. ( Ahnen, DJ; Alberts, DS; Ashbeck, EL; Bhattacharyya, A; Boland, CR; Buckmeier, J; Chow, HH; Fales, L; Fay, DE; Green, S; Hamilton, SR; Heigh, RI; Hsu, CH; Jacobs, E; Lance, P; Martinez, ME; Roe, DJ; Thompson, P; Wang, F, 2012)
" The Adenoma Prevention with Celecoxib (APC) trial showed that the anti-inflammatory drug celecoxib prevents recurrence of colorectal adenoma but increases risk of cardiovascular events."	9.15	C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. ( Bertagnolli, MM; Chan, AT; Hawk, ET; Ridker, PM; Sima, CS; Zauber, AG, 2011)
" Overall, celecoxib was associated with a dose-dependent reduction in adenoma, compared with placebo, with relative risks (RR) of 0."	9.14	Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. ( Bertagnolli, MM; Breazna, A; Chan, AT; Eagle, CJ; Hawk, ET; Hsu, M; Hunter, DJ; Rosenstein, RB; Zauber, AG, 2009)
"The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of the cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention in patients at high risk for colorectal cancer."	9.14	Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. ( Bagheri, D; Bertagnolli, MM; Breazna, A; Burn, J; Chung, DC; Collins, NT; Dewar, T; Eagle, CJ; Foley, TR; Hawk, ET; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Sylwestrowicz, T; Tang, J; Umar, A; Zauber, AG, 2009)
"Celecoxib is approved as an adjunctive chemopreventive agent in adults with familial adenomatous polyposis (FAP)."	9.14	The safety and efficacy of celecoxib in children with familial adenomatous polyposis. ( Ayers, GD; Burke, CA; Church, J; Eagle, C; Half, E; Hasson, H; Hawk, E; Lynch, PM; Patterson, S; Richmond, E; Woloj, M, 2010)
"The Adenoma Prevention With Celecoxib (APC) trial studied celecoxib 200 mg twice daily and 400 mg twice daily and the Prevention of Spontaneous Adenomatous Polyps (PreSAP) trial used 400 mg once daily totest the efficacy and safety of celecoxib against placebo in reducing colorectal adenoma recurrence after polypectomy."	9.12	Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. ( Arber, N; Bertagnolli, MM; Eagle, C; Finn, P; Fowler, R; Hawk, E; Lechuga, M; Levin, B; McMurray, JJ; Pfeffer, MA; Solomon, SD; Wittes, J; Zauber, AG, 2006)
"These findings indicate that celecoxib is an effective agent for the prevention of colorectal adenomas but, because of potential cardiovascular events, cannot be routinely recommended for this indication."	9.12	Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006)
" Of the 557 subjects in the placebo group and the 840 subjects in the celecoxib group who were included in the efficacy analysis, 264 and 270, respectively, were found to have at least one adenoma at year 1, at year 3, or both."	9.12	Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006)
"Discovery phase: 1,406 Caucasian patients (139 advanced adenoma cases and 1,267 controls) from the Adenoma Prevention with Celecoxib (APC) trial were included in a genome-wide association study (GWAS) to identify variants associated with postpolypectomy disease recurrence."	8.89	Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. ( Baird, PN; Bertagnolli, MM; Carvajal-Carmona, LG; Chu, JH; Dunlop, M; Gibbs, P; Houlston, RS; Kubo, M; Lipton, L; Martin, NG; Matsuda, K; Montgomery, GW; Nakamura, Y; Ratain, MJ; Sieber, O; Tomlinson, I; Wang, J; Weiss, ST; Young, J; Zauber, AG, 2013)
" It is our hypothesis that expression of 15-LOX-1 is reduced in human colorectal cancer (CRC) and the administration of celecoxib can reverse this process and induce apoptosis."	7.73	Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. ( Arnoletti, JP; Bland, KI; Boedefeld, W; Frolov, A; Hawkins, A; Heslin, MJ; Soong, R; Urist, MM, 2005)
"For patients at high risk of colorectal cancer, statins do not protect against colorectal neoplasms and may even increase the risk of developing colorectal adenomas."	6.75	Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. ( Bertagnolli, MM; Eagle, CJ; Hawk, ET; Hsu, M; Zauber, AG, 2010)
"Oxylipins derived from arachidonic acid (ARA) have been implicated in the development of colorectal adenomas and colorectal cancer."	5.41	A Protective Role for Arachidonic Acid Metabolites against Advanced Colorectal Adenoma in a Phase III Trial of Selenium. ( Chew, WM; Chow, HS; Ellis, NA; Jacobs, ET; Lance, P; Martinez, JA; Saboda, K; Skiba, MB, 2021)
"HT-29 colon cancer cells and LT97 colorectal micro-adenoma cells derived from a patient with FAP, were exposed to low dose celecoxib and UDCA alone or in combination with tauro-cholic acid (CA) and tauro-chenodeoxycholic acid (CDCA), mimicking bile of FAP patients treated with UDCA."	5.38	Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells. ( Marian, B; Nagengast, FM; Peters, WH; Roelofs, HM; Te Morsche, RH; van Heumen, BW, 2012)
"In the placebo and celecoxib arms of 356 participants each, adenoma detection was 47."	5.22	Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial. ( Ahnen, DJ; Alberts, DS; Ashbeck, EL; Bhattacharyya, A; Boland, CR; Buckmeier, J; Chow, SH; Fales, L; Fay, DE; Hamilton, SR; Heigh, RI; Hsu, CH; Jacobs, ET; Lance, P; Martinez, EM; Roe, DJ; Thompson, PA; Wang, F, 2016)
"Genetic polymorphisms in multiple inflammation-related genes appear to interact with celecoxib on adenoma recurrence and its attendant toxicity, particularly cardiovascular toxicity/symptoms."	5.17	Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. ( Arber, N; Coghill, AE; Duggan, D; Galazan, L; Gigic, B; Hummler, S; Kazanov, D; Kotzmann, J; Kraus, S; Makar, KW; Naumov, I; Poole, EM; Scherer, D; Toriola, AT; Ulrich, CM, 2013)
"COX inhibitors reduce colorectal adenoma recurrence by up to 45% and selenium supplementation may prevent colorectal cancer."	5.16	Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention. ( Ahnen, DJ; Alberts, DS; Ashbeck, EL; Bhattacharyya, A; Boland, CR; Buckmeier, J; Chow, HH; Fales, L; Fay, DE; Green, S; Hamilton, SR; Heigh, RI; Hsu, CH; Jacobs, E; Lance, P; Martinez, ME; Roe, DJ; Thompson, P; Wang, F, 2012)
" The Adenoma Prevention with Celecoxib (APC) trial showed that the anti-inflammatory drug celecoxib prevents recurrence of colorectal adenoma but increases risk of cardiovascular events."	5.15	C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. ( Bertagnolli, MM; Chan, AT; Hawk, ET; Ridker, PM; Sima, CS; Zauber, AG, 2011)
" Overall, celecoxib was associated with a dose-dependent reduction in adenoma, compared with placebo, with relative risks (RR) of 0."	5.14	Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. ( Bertagnolli, MM; Breazna, A; Chan, AT; Eagle, CJ; Hawk, ET; Hsu, M; Hunter, DJ; Rosenstein, RB; Zauber, AG, 2009)
"The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of the cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention in patients at high risk for colorectal cancer."	5.14	Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. ( Bagheri, D; Bertagnolli, MM; Breazna, A; Burn, J; Chung, DC; Collins, NT; Dewar, T; Eagle, CJ; Foley, TR; Hawk, ET; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Sylwestrowicz, T; Tang, J; Umar, A; Zauber, AG, 2009)
"Celecoxib is approved as an adjunctive chemopreventive agent in adults with familial adenomatous polyposis (FAP)."	5.14	The safety and efficacy of celecoxib in children with familial adenomatous polyposis. ( Ayers, GD; Burke, CA; Church, J; Eagle, C; Half, E; Hasson, H; Hawk, E; Lynch, PM; Patterson, S; Richmond, E; Woloj, M, 2010)
"The Adenoma Prevention With Celecoxib (APC) trial studied celecoxib 200 mg twice daily and 400 mg twice daily and the Prevention of Spontaneous Adenomatous Polyps (PreSAP) trial used 400 mg once daily totest the efficacy and safety of celecoxib against placebo in reducing colorectal adenoma recurrence after polypectomy."	5.12	Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. ( Arber, N; Bertagnolli, MM; Eagle, C; Finn, P; Fowler, R; Hawk, E; Lechuga, M; Levin, B; McMurray, JJ; Pfeffer, MA; Solomon, SD; Wittes, J; Zauber, AG, 2006)
"These findings indicate that celecoxib is an effective agent for the prevention of colorectal adenomas but, because of potential cardiovascular events, cannot be routinely recommended for this indication."	5.12	Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006)
" Of the 557 subjects in the placebo group and the 840 subjects in the celecoxib group who were included in the efficacy analysis, 264 and 270, respectively, were found to have at least one adenoma at year 1, at year 3, or both."	5.12	Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006)
"Discovery phase: 1,406 Caucasian patients (139 advanced adenoma cases and 1,267 controls) from the Adenoma Prevention with Celecoxib (APC) trial were included in a genome-wide association study (GWAS) to identify variants associated with postpolypectomy disease recurrence."	4.89	Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. ( Baird, PN; Bertagnolli, MM; Carvajal-Carmona, LG; Chu, JH; Dunlop, M; Gibbs, P; Houlston, RS; Kubo, M; Lipton, L; Martin, NG; Matsuda, K; Montgomery, GW; Nakamura, Y; Ratain, MJ; Sieber, O; Tomlinson, I; Wang, J; Weiss, ST; Young, J; Zauber, AG, 2013)
"The expression of the putative markers LGR-5 (leucine-rich-repeat-containing G-protein-coupled receptor 5), MSI-1 (Musashi-1) and DCAMKL-1 (doublecortin and calcium/calmodulin-dependent protein kinase-like-1) was studied in normal colon mucosa (NM), in the precancerous lesions Mucin Depleted Foci (MDF) and in macroscopic tumours (adenomas) of 1,2-dimethylhydrazine-treated rats."	3.79	Expression of LGR-5, MSI-1 and DCAMKL-1, putative stem cell markers, in the early phases of 1,2-dimethylhydrazine-induced rat colon carcinogenesis: correlation with nuclear β-catenin. ( Caderni, G; Dolara, P; Femia, AP; Salvadori, M, 2013)
" It is our hypothesis that expression of 15-LOX-1 is reduced in human colorectal cancer (CRC) and the administration of celecoxib can reverse this process and induce apoptosis."	3.73	Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. ( Arnoletti, JP; Bland, KI; Boedefeld, W; Frolov, A; Hawkins, A; Heslin, MJ; Soong, R; Urist, MM, 2005)
" On short-term administration, the selective COX-2 inhibitor celecoxib inhibits adenoma growth in animal tumor models, including the C57BL/6J-Min/+ (Min/+) mouse."	3.73	Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor. ( Bertagnolli, MM; Carothers, AM; Cho, NL; Moran, AE; Redston, M, 2006)
"Our base-case analysis assumed a 50% risk reduction in the incidence of adenomas among patients using celecoxib."	3.71	Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis. ( Arguedas, MR; Heudebert, GR; Wilcox, CM, 2001)
"Treatment with celecoxib for 6 months, with before-treatment and after-treatment videos posted to an intranet with an interactive site for scoring."	2.78	Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a web-based tool. ( Khalaf, R; Levin, B; Lynch, PM; Morris, JS; Posadas, J; Rodriguez-Bigas, MA; Ross, WA; Sepeda, VO; Shureiqi, I; Weber, DM, 2013)
"For patients at high risk of colorectal cancer, statins do not protect against colorectal neoplasms and may even increase the risk of developing colorectal adenomas."	2.75	Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. ( Bertagnolli, MM; Eagle, CJ; Hawk, ET; Hsu, M; Zauber, AG, 2010)
"HT-29 colon cancer cells and LT97 colorectal micro-adenoma cells derived from a patient with FAP, were exposed to low dose celecoxib and UDCA alone or in combination with tauro-cholic acid (CA) and tauro-chenodeoxycholic acid (CDCA), mimicking bile of FAP patients treated with UDCA."	1.38	Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells. ( Marian, B; Nagengast, FM; Peters, WH; Roelofs, HM; Te Morsche, RH; van Heumen, BW, 2012)
"Developing a strategy for preventing colorectal cancer by inhibiting COX-2 depends on research advances in several key areas, including predictive biomarkers to identify people at the lowest risk for cardiovascular events, the molecular mechanisms whereby interdicting the COX-2 pathway produces thrombotic events, and the pharmacology of the widely divergent agents that act on COX-2 and its downstream pathway."	1.37	Cardiovascular risk markers and mechanisms in targeting the COX pathway for colorectal cancer prevention. ( Oates, JA, 2011)
" We demonstrate that a reduction of cyclooxygenase 2 gene dosage rescued the ovarian aging phenotype of the Wv mice, whereas homozygous deletion was accompanied by a compensatory increase in ovarian cyclooxygenase 1 expression and prostaglandin E(2) synthesis."	1.34	A reduction of cyclooxygenase 2 gene dosage counters the ovarian morphological aging and tumor phenotype in Wv mice. ( Cai, KQ; Hamilton, TC; Klein-Szanto, A; Smedberg, JL; Smith, ER; Xu, XX; Yang, WL, 2007)
"Most colorectal cancers are believed to develop from colorectal adenomas."	1.32	The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. ( Bardou, M; Barkun, AN; Rahme, E; Toubouti, Y, 2003)
"The ratios of squamous cell carcinomas to papillomas and of sebaceous gland adenomas to papillomas plus squamous cell carcinomas were increased markedly in transgenic mice treated with DMBA alone compared with DMBA/phorbol 12-myristate 13-acetate-treated transgenic and wild-type mice."	1.31	Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. ( Berger, I; Furstenberger, G; Marks, F; Muller-Decker, K; Neufang, G; Neumann, M, 2002)

Research

Studies (45)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Median Selenium Blood Levels at One Year.

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	30 (66.67)	29.6817
2010's	14 (31.11)	24.3611
2020's	1 (2.22)	2.80

Authors	Studies
Martinez, JA	1
Skiba, MB	1
Chow, HS	1
Chew, WM	1
Saboda, K	1
Lance, P	3
Ellis, NA	1
Jacobs, ET	2
Kraus, S	1
Hummler, S	1
Toriola, AT	1
Poole, EM	1
Scherer, D	1
Kotzmann, J	1
Makar, KW	1
Kazanov, D	1
Galazan, L	1
Naumov, I	1
Coghill, AE	1
Duggan, D	1
Gigic, B	1
Arber, N	3
Ulrich, CM	1
Wang, J	1
Carvajal-Carmona, LG	1
Chu, JH	1
Zauber, AG	9
Kubo, M	1
Matsuda, K	1
Dunlop, M	1
Houlston, RS	1
Sieber, O	1
Lipton, L	1
Gibbs, P	1
Martin, NG	1
Montgomery, GW	1
Young, J	1
Baird, PN	1
Ratain, MJ	1
Nakamura, Y	1
Weiss, ST	1
Tomlinson, I	1
Bertagnolli, MM	10
Thompson, PA	1
Ashbeck, EL	2
Roe, DJ	2
Fales, L	2
Buckmeier, J	2
Wang, F	2
Bhattacharyya, A	2
Hsu, CH	2
Chow, SH	1
Ahnen, DJ	2
Boland, CR	2
Heigh, RI	2
Fay, DE	2
Hamilton, SR	2
Martinez, EM	1
Alberts, DS	2
Ignatenko, NA	1
Besselsen, DG	1
Stringer, DE	1
Blohm-Mangone, KA	1
Cui, H	1
Gerner, EW	1
Cho, NL	2
Redston, M	4
Carothers, AM	2
Hornick, J	1
Wilton, A	1
Sontag, S	1
Nishioka, N	1
Giardiello, FM	1
Saltzman, JR	3
Gostout, C	1
Eagle, CJ	6
Hawk, ET	6
Stevens, RG	1
Pretlow, TP	1
Hurlstone, DP	1
Giardina, C	1
Rosenberg, DW	1
Chan, AT	2
Hsu, M	2
Breazna, A	2
Hunter, DJ	1
Rosenstein, RB	4
Dubois, RN	1
Kim, K	2
Tang, J	3
Umar, A	1
Bagheri, D	2
Collins, NT	1
Burn, J	2
Chung, DC	2
Dewar, T	2
Foley, TR	2
Hoffman, N	2
Macrae, F	2
Pruitt, RE	2
Salzberg, B	2
Sylwestrowicz, T	2
Yan, M	1
Myung, SJ	1
Fink, SP	1
Lawrence, E	1
Lutterbaugh, J	1
Yang, P	1
Zhou, X	1
Liu, D	1
Rerko, RM	1
Willis, J	1
Dawson, D	1
Tai, HH	1
Barnholtz-Sloan, JS	1
Newman, RA	1
Markowitz, SD	1
Lynch, PM	3
Ayers, GD	1
Hawk, E	2
Richmond, E	1
Eagle, C	2
Woloj, M	1
Church, J	1
Hasson, H	1
Patterson, S	1
Half, E	1
Burke, CA	1
Meyskens, FL	1
McLaren, CE	1
Oates, JA	1
Sima, CS	1
Ridker, PM	1
Thiel, A	1
Narko, K	2
Heinonen, M	1
Hemmes, A	1
Tomasetto, C	2
Rio, MC	2
Haglund, C	1
Mäkelä, TP	1
Ristimäki, A	2
van Heumen, BW	1
Roelofs, HM	1
Te Morsche, RH	1
Marian, B	1
Nagengast, FM	1
Peters, WH	1
Manzano, A	1
Pérez-Segura, P	1
Thompson, P	1
Green, S	1
Chow, HH	1
Martinez, ME	1
Jacobs, E	1
Morris, JS	1
Ross, WA	1
Rodriguez-Bigas, MA	1
Posadas, J	1
Khalaf, R	1
Weber, DM	1
Sepeda, VO	1
Levin, B	3
Shureiqi, I	1
Femia, AP	1
Dolara, P	1
Salvadori, M	1
Caderni, G	1
Muller-Decker, K	1
Neufang, G	1
Berger, I	1
Neumann, M	1
Marks, F	1
Furstenberger, G	1
Saukkonen, K	1
Rahme, E	1
Barkun, AN	1
Toubouti, Y	1
Bardou, M	1
Topol, EJ	1
Senior, K	1
Husøy, T	1
Knutsen, HK	1
Cruciani, V	1
Olstørn, HB	1
Mikalsen, SO	1
Løberg, EM	1
Alexander, J	1
Heslin, MJ	1
Hawkins, A	1
Boedefeld, W	1
Arnoletti, JP	1
Frolov, A	1
Soong, R	1
Urist, MM	1
Bland, KI	1
Tanaka, S	1
Tatsuguchi, A	1
Futagami, S	1
Gudis, K	1
Wada, K	1
Seo, T	1
Mitsui, K	1
Yonezawa, M	1
Nagata, K	1
Fujimori, S	1
Tsukui, T	1
Kishida, T	1
Sakamoto, C	1
Oviedo, JA	1
Schroy, PC	1
Raskov, HH	1
Moran, AE	1
Solomon, SD	3
Pfeffer, MA	1
McMurray, JJ	1
Fowler, R	2
Finn, P	1
Lechuga, M	1
Wittes, J	3
Corle, D	1
Hess, TM	1
Woloj, GM	1
Boisserie, F	1
Anderson, WF	1
Viner, JL	1
Gordon, GB	1
Spicak, J	1
Rácz, I	1
Dite, P	1
Hajer, J	1
Zavoral, M	1
Lechuga, MJ	1
Gerletti, P	1
Macdonald, K	1
Bhadra, P	1
Psaty, BM	1
Potter, JD	1
Lee, YH	1
Ji, JD	1
Song, GG	1
Armstrong, DJ	1
Andersohn, F	1
Suissa, S	1
Garbe, E	1
Cen, YY	1
Yang, WL	1
Cai, KQ	1
Smedberg, JL	1
Smith, ER	1
Klein-Szanto, A	1
Hamilton, TC	1
Xu, XX	1
Tuma, R	1
Arguedas, MR	1
Heudebert, GR	1
Wilcox, CM	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase I Pilot Toxicity/Methods Validation Study of Celecoxib in Genotype-Positive Children With Familial Adenomatous Polyposis[NCT00685568]	Phase 1	22 participants (Actual)	Interventional	2002-11-21	Completed
Prevention of Sporadic Colorectal Adenomas With Celecoxib[NCT00005094]	Phase 3	1,170 participants (Anticipated)	Interventional	2000-03-31	Completed
Phase III Study of the Effects of Selenium on Adenomatous Polyp Recurrence[NCT00078897]	Phase 3	1,621 participants (Actual)	Interventional	2005-01-20	Terminated (stopped due to Concluded - Terminated by PI)
Molecular Targeting of 15-LOX-1 for Apoptosis Induction in Human Colorectal Cancers[NCT00503035]	Phase 2	51 participants (Actual)	Interventional	2003-08-20	Completed
Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)[NCT00141193]	Phase 3	1,561 participants (Actual)	Interventional	2001-02-28	Completed
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614]	Phase 2	58 participants (Actual)	Interventional	2003-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Adequate adherence to long-term selenium treatment as measured by blood selenium levels (ng/mL) at one year. (NCT00078897)
Timeframe: One year

Number of Recurrent Adenomas at Surveillance Colonoscopy

Intervention	ng/mL (Median)
Selenium	205.4
Placebo	140.0

Detection of metachronous colorectal adenomas during follow-up, by treatment, in the original cohort. Surveillance colonoscopy is recommended 3 to 5 years after removal of colorectal adenoma(s). Participants will remain on the study intervention until their surveillance colonoscopy. Surveillance colonoscopy is determined by participants' GI physician. (NCT00078897)
Timeframe: 3 to 5 years after baseline colonoscopy

13-HODE Colonic Tissue Levels

Intervention	Adenomas (Number)
Selenium	302
Placebo	295

13-HODE colonic tissue levels measured by Liquid chromatography and tandem mass spectrometry measurements (LC/MS/MS) in colorectal normal and polyp tissues (NCT00503035)
Timeframe: Baseline to post 6 months of celecoxib treatment

PGE2 Colonic Tissue Levels

Intervention	ng/mg tissue protein (Mean)
	polyps before celecoxib treatment	polyps after celecoxib treatment	Normal: before celecoxib treatment	Normal: after celecoxib treatment
Celecoxib	14.56	18.83	23.02	20.03

PGE2 colonic tissue levels measured by Liquid chromatography and tandem mass spectrometry measurements (LC/MS/MS) in colorectal normal and polyp tissues (NCT00503035)
Timeframe: at the baseline colonoscopy (or sigmoidoscopy in patients who had undergone colectomy) before the initiation of celecoxib, and the follow-up colonoscopy or sigmoidoscopy was performed after celecoxib treatment (month 6)

Intervention	ng/mg tissue protein (Mean)
	Polyps: before celecoxib treatment	Polyps: after celecoxib treatment	Normal: before celecoxib treatment	Normal: after celecoxib treatment
Celecoxib	14.71	20.62	21.48	24.99

Article	Year
A Protective Role for Arachidonic Acid Metabolites against Advanced Colorectal Adenoma in a Phase III Trial of Selenium. Nutrients, 2021, Oct-29, Volume: 13, Issue:11 Topics: Adenoma; Aged; Arachidonic Acid; Celecoxib; Colorectal Neoplasms; Dietary Supplements; Disease Progr	2021
Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. Pharmacogenetics and genomics, 2013, Volume: 23, Issue:8 Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Col	2013
Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial. Journal of the National Cancer Institute, 2016, Volume: 108, Issue:12 Topics: Adenoma; Aged; Cardiovascular Diseases; Celecoxib; Colonoscopy; Colorectal Neoplasms; Cyclooxygenase	2016
Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer prevention research (Philadelphia, Pa.), 2008, Volume: 1, Issue:1 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Biomarkers; Celecoxib; C	2008
Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology, 2009, Volume: 136, Issue:7 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Celecoxib; Colorectal Neopla	2009
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:4 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colonoscopy; Colorectal	2009
15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proceedings of the National Academy of Sciences of the United States of America, 2009, Jun-09, Volume: 106, Issue:23 Topics: Adenoma; Animals; Celecoxib; Colon; Colonic Neoplasms; Colonoscopy; Drug and Narcotic Control; Human	2009
The safety and efficacy of celecoxib in children with familial adenomatous polyposis. The American journal of gastroenterology, 2010, Volume: 105, Issue:6 Topics: Adenoma; Adenomatous Polyposis Coli; Adolescent; Celecoxib; Child; Cohort Studies; Colonic Neoplasms	2010
Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:5 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cardiovascular Diseases; Celecoxib;	2010
C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:8 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; C-Reactive Protein; Cardiovascular	2011
Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention. Cancer prevention research (Philadelphia, Pa.), 2012, Volume: 5, Issue:12 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Body Mass Index; Celecoxib; Cohort Studies; Colorectal Neop	2012
Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a web-based tool. Gastrointestinal endoscopy, 2013, Volume: 77, Issue:3 Topics: Adenoma; Adenomatous Polyposis Coli; Adolescent; Adult; Antineoplastic Agents; Celecoxib; Colorectal	2013
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation, 2006, Sep-05, Volume: 114, Issue:10 Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Car	2006
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation, 2006, Sep-05, Volume: 114, Issue:10 Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Car	2006
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation, 2006, Sep-05, Volume: 114, Issue:10 Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Car	2006
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation, 2006, Sep-05, Volume: 114, Issue:10 Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Car	2006
Celecoxib for the prevention of sporadic colorectal adenomas. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas	2006
Celecoxib for the prevention of sporadic colorectal adenomas. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas	2006
Celecoxib for the prevention of sporadic colorectal adenomas. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas	2006
Celecoxib for the prevention of sporadic colorectal adenomas. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas	2006
Celecoxib for the prevention of colorectal adenomatous polyps. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal	2006
Celecoxib for the prevention of colorectal adenomatous polyps. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal	2006
Celecoxib for the prevention of colorectal adenomatous polyps. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal	2006
Celecoxib for the prevention of colorectal adenomatous polyps. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal	2006
Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk. Rheumatology international, 2007, Volume: 27, Issue:5 Topics: Adenoma; Adenomatous Polyps; Angina, Unstable; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactone	2007

Article	Year
Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis. Nutrition and cancer, 2008, Volume: 60 Suppl 1 Topics: Adenoma; Adenomatous Polyposis Coli; Animals; Biogenic Polyamines; Celecoxib; Chemoprevention; Eflor	2008
Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial". Cancer prevention research (Philadelphia, Pa.), 2008, Volume: 1, Issue:3 Topics: Adenoma; Antineoplastic Agents; Biomarkers; Celecoxib; Chemoprevention; Clinical Trials as Topic; Co	2008
Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy? Journal of the National Cancer Institute, 2010, Dec-15, Volume: 102, Issue:24 Topics: Adenoma; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Squamous Cell;	2010
Cardiovascular risk markers and mechanisms in targeting the COX pathway for colorectal cancer prevention. Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:8 Topics: Adenoma; Anticarcinogenic Agents; C-Reactive Protein; Celecoxib; Colorectal Neoplasms; Female; Human	2011
Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice. International journal of cancer, 2012, Sep-01, Volume: 131, Issue:5 Topics: Adenoma; Animals; Apoptosis; Blotting, Western; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyc	2012
Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells. Experimental cell research, 2012, Apr-15, Volume: 318, Issue:7 Topics: Adenoma; Adenomatous Polyposis Coli; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cele	2012
Expression of LGR-5, MSI-1 and DCAMKL-1, putative stem cell markers, in the early phases of 1,2-dimethylhydrazine-induced rat colon carcinogenesis: correlation with nuclear β-catenin. BMC cancer, 2013, Feb-01, Volume: 13 Topics: 1,2-Dimethylhydrazine; Adenoma; Animals; beta Catenin; Biomarkers, Tumor; Celecoxib; Cell Nucleus; C	2013
Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2002, Sep-17, Volume: 99, Issue:19 Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenoma; Animals; Carcinogens; Carcinoma, Squamous Cell; Celecoxib	2002
Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice. Cancer research, 2003, Jun-15, Volume: 63, Issue:12 Topics: Adenoma; Angiogenesis Inhibitors; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors;	2003
The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology, 2003, Volume: 125, Issue:2 Topics: Adenoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cel	2003
Arthritis medicines and cardiovascular events--"house of coxibs". JAMA, 2005, Jan-19, Volume: 293, Issue:3 Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyc	2005
COX-2 inhibitors: cancer prevention or cardiovascular risk? The Lancet. Oncology, 2005, Volume: 6, Issue:2 Topics: Adenoma; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy	2005
Connexin43 is overexpressed in Apc(Min/+)-mice adenomas and colocalises with COX-2 in myofibroblasts. International journal of cancer, 2005, Sep-01, Volume: 116, Issue:3 Topics: Adenoma; Adenomatous Polyposis Coli; Animals; Celecoxib; Connexin 43; Cyclooxygenase 2; Cyclooxygena	2005
Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. Annals of surgery, 2005, Volume: 241, Issue:6 Topics: Adenoma; Apoptosis; Arachidonate 15-Lipoxygenase; Blotting, Western; Carcinoma; Celecoxib; Colorecta	2005
Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma. Gut, 2006, Volume: 55, Issue:1 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Ce	2006
Does celecoxib use increase the risk of cardiovascular events? Gastroenterology, 2005, Volume: 129, Issue:4 Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Clinical Trial	2005
Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor. Cancer research, 2006, Jun-15, Volume: 66, Issue:12 Topics: Adenoma; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Administration Schedule	2006
Risks and benefits of celecoxib to prevent recurrent adenomas. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adenomatous Polyps; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celec	2006
Celecoxib and CVS risk--lessons from the APC and PreSAP studies. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:4 Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Colorectal Neo	2007
Risks and benefits of celecoxib to prevent colorectal adenomas. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Adenoma; Cardiovascular Diseases; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Huma	2006
Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory? Gastroenterology, 2006, Volume: 131, Issue:6 Topics: Adenoma; Celecoxib; Chemoprevention; Colonoscopy; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors;	2006
Letter by Cen regarding article, "Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas". Circulation, 2007, Mar-27, Volume: 115, Issue:12 Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Color	2007
A reduction of cyclooxygenase 2 gene dosage counters the ovarian morphological aging and tumor phenotype in Wv mice. The American journal of pathology, 2007, Volume: 170, Issue:4 Topics: Adenoma; Aging; Animals; Blotting, Western; Celecoxib; Cell Transformation, Neoplastic; Cyclooxygena	2007
Drugs to prevent colon cancer show promise, but hurdles remain for chemoprevention. Journal of the National Cancer Institute, 2008, Jun-04, Volume: 100, Issue:11 Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Prot	2008
Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis. Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:5 Topics: Adenoma; Aged; Celecoxib; Chemoprevention; Colonic Polyps; Colonoscopy; Colorectal Neoplasms; Cost-B	2001

celecoxib and Adenoma